Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892226940> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W2892226940 endingPage "5052" @default.
- W2892226940 startingPage "5052" @default.
- W2892226940 abstract "5052 Background: While men with aPC respond to initial treatment, most will progress and require sequential therapies. Due to advances in next-generation sequencing (NGS), it is feasible to assess the tumor genomic landscape via blood or tumor tissue at different time points in treatment. Much debate exists over the concordance of tissue (tDNA) and ctDNA NGS. Some hypothesize that the genomic landscape of aPC evolves with treatment and time; however, there is a paucity of experimental data to support these statements. In this exploratory analysis, we compare the genomic landscape of aPC as detected by commercially available tDNA and ctDNA NGS platforms at different points during the course of disease. Methods: Men with aPC from the Huntsman Cancer Institute, University of Utah with matched tDNA NGS using FoundationOne (Foundation Medicine, Cambridge, MA) and ctDNA NGS using G360 (Guardant Health, Inc., Redwood City, CA) were included. Clinical data was collected retrospectively. Exonic regions from 69 genes covered by both platforms were included for analysis. Paired t-tests were used to assess number of genomic alterations (GAs) between testing platforms and were confirmed with nonparametric testing. Number of alterations was assessed by time and number of treatments between tDNA and ctDNA testing by multivariate nonparametric trend tests. Results: 101 men with aPC who had matched tissue and ctDNA NGS were included. In men with no new treatments and ≤ 1 year between tests, a similar number of GAs were detected in both tests (2.0 vs. 2.2, p=0.78). In contrast, men with ≥ 1 new treatment between tests had significantly more GAs after treatment (5.0 vs. 2.4, p=0.005). Total number of GAs was correlated with number of new treatments between testing (p=0.003) and not time between testing (p=0.76). Conclusions: In these hypothesis-generating data, the genomic landscape of aPC evolves with subsequent therapies. These data suggest that, in addition to baseline tumor genomic profiling, a contemporary tumor genomic profile at the time of disease progression may optimize guidance towards subsequent therapy selection." @default.
- W2892226940 created "2018-09-27" @default.
- W2892226940 creator A5009315642 @default.
- W2892226940 creator A5022744341 @default.
- W2892226940 creator A5024053204 @default.
- W2892226940 creator A5024065466 @default.
- W2892226940 creator A5053151806 @default.
- W2892226940 creator A5055269586 @default.
- W2892226940 creator A5061173051 @default.
- W2892226940 creator A5080507578 @default.
- W2892226940 creator A5088144108 @default.
- W2892226940 date "2018-05-20" @default.
- W2892226940 modified "2023-09-26" @default.
- W2892226940 title "Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC) over treatment and time." @default.
- W2892226940 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.5052" @default.
- W2892226940 hasPublicationYear "2018" @default.
- W2892226940 type Work @default.
- W2892226940 sameAs 2892226940 @default.
- W2892226940 citedByCount "1" @default.
- W2892226940 countsByYear W28922269402019 @default.
- W2892226940 crossrefType "journal-article" @default.
- W2892226940 hasAuthorship W2892226940A5009315642 @default.
- W2892226940 hasAuthorship W2892226940A5022744341 @default.
- W2892226940 hasAuthorship W2892226940A5024053204 @default.
- W2892226940 hasAuthorship W2892226940A5024065466 @default.
- W2892226940 hasAuthorship W2892226940A5053151806 @default.
- W2892226940 hasAuthorship W2892226940A5055269586 @default.
- W2892226940 hasAuthorship W2892226940A5061173051 @default.
- W2892226940 hasAuthorship W2892226940A5080507578 @default.
- W2892226940 hasAuthorship W2892226940A5088144108 @default.
- W2892226940 hasConcept C121608353 @default.
- W2892226940 hasConcept C126322002 @default.
- W2892226940 hasConcept C143998085 @default.
- W2892226940 hasConcept C160798450 @default.
- W2892226940 hasConcept C2780192828 @default.
- W2892226940 hasConcept C32220436 @default.
- W2892226940 hasConcept C60644358 @default.
- W2892226940 hasConcept C70721500 @default.
- W2892226940 hasConcept C71924100 @default.
- W2892226940 hasConcept C86803240 @default.
- W2892226940 hasConceptScore W2892226940C121608353 @default.
- W2892226940 hasConceptScore W2892226940C126322002 @default.
- W2892226940 hasConceptScore W2892226940C143998085 @default.
- W2892226940 hasConceptScore W2892226940C160798450 @default.
- W2892226940 hasConceptScore W2892226940C2780192828 @default.
- W2892226940 hasConceptScore W2892226940C32220436 @default.
- W2892226940 hasConceptScore W2892226940C60644358 @default.
- W2892226940 hasConceptScore W2892226940C70721500 @default.
- W2892226940 hasConceptScore W2892226940C71924100 @default.
- W2892226940 hasConceptScore W2892226940C86803240 @default.
- W2892226940 hasIssue "15_suppl" @default.
- W2892226940 hasLocation W28922269401 @default.
- W2892226940 hasOpenAccess W2892226940 @default.
- W2892226940 hasPrimaryLocation W28922269401 @default.
- W2892226940 hasRelatedWork W1982503259 @default.
- W2892226940 hasRelatedWork W2604161311 @default.
- W2892226940 hasRelatedWork W2810602217 @default.
- W2892226940 hasRelatedWork W2915965072 @default.
- W2892226940 hasRelatedWork W2962601203 @default.
- W2892226940 hasRelatedWork W3135130571 @default.
- W2892226940 hasRelatedWork W4238821541 @default.
- W2892226940 hasRelatedWork W4320914613 @default.
- W2892226940 hasRelatedWork W2189427681 @default.
- W2892226940 hasRelatedWork W2530851007 @default.
- W2892226940 hasVolume "36" @default.
- W2892226940 isParatext "false" @default.
- W2892226940 isRetracted "false" @default.
- W2892226940 magId "2892226940" @default.
- W2892226940 workType "article" @default.